Modavar is working on formulating topical products for ANDA approval, as well as unique, innovative 505(b)(2) products in our FDA approved Frederick, Maryland plant. In addition, Cadila Pharmaceuticals is actively working on ANDA formulation development for Modavar and on a co-development basis with other partners.

We have 23 FDA-approved products and 9 filed ANDAs with the US FDA. In addition, 7 ANDA projects are in the pipeline for development and submission. We are also working on multiple formulations with partners on a co-development basis for the U.S. market.

The capabilities of our manufacturing facilities include: